Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. The Journal of cell biology 2005 Dec; 171(6).

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer research 2005 Dec; 65(23).

Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. A CD8/Lck transgene is able to drive thymocyte differentiation. Journal of immunology (Baltimore, Md. : 1950) 2006 Nov; 177(9).

Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009 Sep; 461(7260).

Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PloS one 2010; 5(7).

Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast cancer research and treatment 2011 Jul; 128(1).

Lawrence RT, Perez EM, Hernández D, Miller CP, Haas KM, Irie HY, Lee SL, C. Blau CA, Villén J. The proteomic landscape of triple negative breast cancer. Cell Reports 2015; 11:630-644.

Ito K, Park SH, Nayak A, Byerly J, Irie HY. PTK6 inhibition suppresses metastases of triple negative breast cancer cells via SNAIL-dependent E-cadherin regulation. Cancer Research 2016; 76:4406.

Lee E, Ito K, Zhao Y, Schadt EE, Irie HY, Zhu J. Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers. Bioinformatics 2016; 32:96-105.

Katsyv I, Wang M, Song WM, Zhou X, Zhao Y, Park S, Zhu J, Zhang B, Irie HY. EPRS is a critical  regulator of cell proliferation and estrogen signaling in ER+ breast cancer. Oncotarget 2016; 7:69592

Byerly J, Halstead-Nussloch G, Ito K, Katsyv I and Irie HY. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple negative breast cancer cells. Breast Cancer Research 2016; 18:95

Ito K, Park S, Katsyv I, Zhang W, De Angelis C, Schiff R, Irie HY. PTK6 regulates survival of endocrine therapy resistant ER+ breast cancer cells. NPJ Breast Cancer (doi: 10.1038/s41523-017-0047-1. eCollection 2017)

Zhou X, Wang M, Katsyv I, Irie H, Zhang B. EMUDRA: Ensemble of multiple drug repositioning approaches to improve prediction accuracy. Bioinformatics 2018; 34:3151-3159.

Byerly J, Port ER, Irie HY. PRKCQ inhibition enhances chemosensitivity of triple negative breast cancer by regulating Bim. Breast Cancer Research, 2020; 22:72.

Sato K, Padgaonkar A, Baker S, Cosenza S, Rechkoblit O, Venkata Subbaiah V, Domingo-Domenech J, Bartkowski A, Port E, Aggarwal A, Reddy M, Irie HY*, Reddy EP* (co-senior, co-corresponding author) Simultaneous CK2/TNIK/Dyrk1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Communications. 2021; 12: 4671.